Tuesday, October 1, 2013

• Interim Data for Merck’s MK-3475, an Investigational Anti-PD-1 Immunotherapy, in Previously Treated Patients with Non-Small Cell Lung Cancer to be Presented at 15th World Conference on Lung CancerBusiness Wire( (Tue, Oct 1)
• Data from Merck’s Investigational Hepatitis C Treatment Portfolio to be Presented at the 64th American Association for the Study of Liver Diseases Annual MeetingBusiness Wire( (Tue, Oct 1)
• Merck Updates Plans for Headquarters Move in New JerseyBusiness Wire( (Tue, Oct 1)
• Merck Announces Global Initiative to Sharpen Commercial and R&D FocusBusiness Wire( (Tue, Oct 1)

Saturday, September 28, 2013

• Merck Animal Health Proudly Supports Vaccination Programs Targeted at Reducing Disease in Domestic PetsBusiness Wire( (Sat, Sep 28)

Friday, September 27, 2013

• Merck to Hold Third-Quarter 2013 Sales and Earnings Conference Call on October 28Business Wire( (Fri, Sep 27)

Monday, September 23, 2013

• Merck Receives Complete Response Letter for Investigational Medicine Sugammadex Sodium InjectionBusiness Wire( (Mon, Sep 23)

Wednesday, September 11, 2013

• Merck and AstraZeneca Enter License Agreement for Investigational Oral WEE1 Kinase Inhibitor Therapy for CancerBusiness Wire( (Wed, Sep 11)

Tuesday, September 10, 2013

• Merck to Present at the Morgan Stanley Global Healthcare ConferenceBusiness Wire( (Tue, Sep 10)

Monday, September 9, 2013

• New Survey of People Living with HIV Shows Desire for Greater Doctor-Patient Dialogue about Treatment and Disease ImpactPR Newswire( (Mon, Sep 9)
• Merck Announces FDA Acceptance of New Drug Application for Investigational Fertility TreatmentBusiness Wire( (Mon, Sep 9)